Pharma stocks battered, many touch new lows

Shares of pharmaceutical companies got hammered down in the Monday stock market meltdown amid the tariff war set in motion last week by the U.S. with its reciprocal tariffs.

All 20 companies forming part of the Nifty Pharma were in the red even as the sectoral index of the National Stock Exchange ended 2.75% lower at 19,995.50 points. Of them, shares of as many as six companies touched their 52-week low.

While Aurobindo Pharma, Dr. Reddy’s Laboratories and Zydus Lifesciences shares opened at their 52-week low, Gland Pharma, Natco Pharma and JB Chemicals and Pharmaceuticals shares touched a new low intra-day on the NSE. Cipla shares on BSE touched 52-week low.

The decline in the shares prices of the 20 companies part of Nifty Pharma index ranged from less than 1% to as much as 6% with Biocon ending 5.99% lower at ₹308.15 each.

Though pharma did not figure in the list of goods that face the reciprocal tariff, the fear of being slapped with the levy remains for the drug makers. Hours after unleashing reciprocal tariffs, U.S. President Donald Trump had told media the tariff for pharma and semiconductors is also on the cards. It will “happen in near future… under review right now. Looking at pharma as a separate category and will be announcing that in not too distant future,” he had said, adding the tariff will be at a level never seen before.

  • Related Posts

    Rajasthan Bans 7 Sub-Standard Medicines

    Prioritising public health and patient safety, the Commissionerate of Food Safety and Drug Control, Rajasthan, has issued an alert regarding seven medicines and declared them “Not of Standard Quality”. Prioritising…

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    To Eat or not to Eat, if this Dilemma is ‘Eating’ you, ‘Eat’ this Book

    To Eat or not to Eat, if this Dilemma is ‘Eating’ you, ‘Eat’ this Book

    NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

    NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

    Rajasthan Bans 7 Sub-Standard Medicines

    Rajasthan Bans 7 Sub-Standard Medicines

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Obesity drug market to gain as Indians pop the pill and Chinese bring more

    Obesity drug market to gain as Indians pop the pill and Chinese bring more